1. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006; 38: 441 - 446.

2. McGirt L.Y., Beck L.A. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006; 118: 202 - 208.

3. Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013; 2(3) e24137.

4. Gandhi N.A., Pirozzi G., Graham N.M. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017; 13(5): 425 - 437.

5. Werfel T., Allam J.P., Biedermann T. et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138: 336 - 349.

6. Wollenberg A., Barbarot S., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.J Eur Acad Dermatol Venereol. 2018; 32(5): 657 - 682.

7. Кубанов А.А., Богданова Е.В. Организация и результаты оказания медицинской помощи по профилю дерматовенерология в Российской Федерации. Итоги 2018 года. Вестник дерматологии и венерологии. 2019; 95 (4): 8 - 23.

8. Schneider L., Hanifin J., Boguniewicz M. et al. Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol. 2016; 33(4): 388 - 398.

9. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012; 67 (12); 1475 - 1482.

10. van der Hulst A.E., Klip H., Brand P.L. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007; 120: 565 - 569.

11. Eckert L., Gupta S., Amand C. et al. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol 2018; 78: 54 - 61.

12. Illi S., von Mutius E., Lau S. et al. The pattern of atopic sensitization is associated with the development of asthma in childhood. J Allergy Clin Immunol. 2001; 108: 709 - 714.

13. Aw M., Penn J., Gauvreau G.M. et al. Atopic March: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020; 181(1): 1 - 10.

14. Spergel J.M. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin N Am. 2010; 30: 269 - 280.

15. Hill D.A., Spergel J.M. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018; 120(2): 131 - 137.

16. Williams H., Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006; 118: 209 - 213.

17. Illi S., von Mutius E., Lau S. et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004; 113: 925 - 931.

18. Атопический дерматит: рекомендации для практических врачей. Российский согласительный национальный документ по атопическому дерматиту. Под ред. Р.М. Хаитова, А.А. Кубановой. М.: Фармакус Принт, 2002. 192 с.

19. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980; 92(Suppl): 44 - 47.

20. Eichenfield L.F., Tom W.L., Chamlin S.L. et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014; 70(2): 338 - 351.

21. Ryan C., Amor K.T., Menter A. The use of cyclosporine in dermatology: part II.J Am Acad Dermatol. 2010; 63(6): 949 - 972.

22. Arbes S.J. Jr. Gergen P.J., Elliott L., Zeldin D.C. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005; 116: 377 - 383.

23. Клиническая дерматовенерология: в 2 т. / под ред. Ю.К. Скрипкина, Ю.С. Бутова. - М.: ГЭОТАР-Медиа, 2009. - т. II. - 928 с.

24. Futamura M., Leshem Y.A., Thomas K.S. et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016; 74(2): 288 - 294.

25. Oranje A.P., Stalder J.F., Taieb A. et al. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol. 1997; 8: 28 - 34.

26. Schram M.E., Spuls P.I., Leeflang M.M. et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012; 67: 99 - 106.

27. Giam Y.C., Hebert A.A., Dizon M.V. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016; 6(2): 120 - 128.

28. Breternitz M., Kowatzki D., Langenauer M. et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008; 21: 39 - 45.

29. Verallo-Rowell V.M., Dillague K.M., Syah-Tjundawan B.S. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. 2008; 19(6): 308 - 315.

30. Simpson E., Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011; 10: 744 - 749.

31. Lindh J.D., Bradley M. Clinical effectiveness of moisturizers in atopic dermatitis and related disorders: a systematic review. Am J Clin Dermatol. 2015; 16: 341 - 359.

32. Miller D.W., Koch S.B., Yentzer B.A. et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011; 10: 531 - 537.

33. Grimalt R., Mengeaud V., Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007; 214 (1): 61 - 67.

34. Msika P., De Belilovsky C., Piccardi N. et al. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol. 2008; 25 (6): 606 - 612.

35. Lucky A.W., Leach A.D., Laskarzewski P., Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997; 14 (4): 321 - 324.

36. Eberlein B., Eicke C., Reinhardt H.W., Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008; 22 (1): 73 - 82.

37. Sugarman J.L., Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009; 8 (12): 1106 - 1111.

38. Leung T.N., Chow C.M., Chow M.P. et al. Clinical guidelines on management of atopic dermatitis in children. Hong Kong J Paediatr (new series). 2013; 18: 96 - 104.

39. Darsow U., Wollenberg A., Simon D. et al. ETFAD/EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010; 24 (3): 317 - 328.

40. Chiang C., Eichenfield L.F. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol. 2009; 26 (3): 273 - 278.

41. Guidance on Prescribing. In: British National Formulary No. 60. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.

42. Dabade T.S., Davis D.M., Wetter D.A. et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012; 67 (1): 100 - 106.

43. Devillers A.C., Oranje A.P. Efficacy and safety of "wet-wrap" dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006; 154 (4): 579 - 585.

44. Devillers A.C., de Waard-van der Spek F.B., Mulder P.G., Oranje A.P. Treatment of refractory atopic dermatitis using "wet-wrap" dressings and diluted corticosteroids: results of standardized treatment in both children and adults. Dermatology. 2002; 204: 50 - 55.

45. Goodyear H.M., Spowart K., Harper J.I. "Wet-wrap" dressings for the treatment of atopic eczema in children. Br J Dermatol. 1991; 125 (6): 604.

46. Brenninkmeijer E.E., Spuls P.I., Lindeboom R. et al. Excimer laser vs. clobetasol propionate 0.05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol. 2010; 163 (4): 823 - 831.

47. Pels R., Sterry W., Lademann J. Clobetasol propionate - where, when, why? Drugs Today (Barc). 2008; 44 (7): 547 - 557.

48. Breneman D., Fleischer A.B. Jr, Kaplan D. et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol. 2005; 4 (3): 330 - 336.

49. Feldman S.R. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. CurrTher Res ClinExp. 2005; 66 (3): 154 - 171.

50. Datz B., Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991; 25 (6 Pt 2): 1157 - 1160.

51. Viglioglia P., Jones M.L., Peets E.A. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res. 1990; 18 (6): 460 - 467.

52. Vanderploeg D.E. Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. South Med J. 1976; 69 (7): 862 - 863.

53. Queille C., Pommarede R., Saurat J.H. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1984; 1 (3): 246 - 253.

54. Cabrera M.E. Treatment of severe or resistant corticosteroid-responsive dermatoses with Diprolene cream. J Int Med Res. 1984; 12 (3): 163 - 169.

55. Lodolo J.C. Diprolene cream in the treatment of severe or resistant corticosteroid-responsive dermatoses. J Int Med Res. 1984; 12 (2): 114 - 120.

56. Peterkin G.A., Morley W.N., Chalmers D. Triamcinolone and fluocinolone acetonide ointments in atopic eczema. BrMed J. 1962; 1 (5289): 1392.

57. Hanifin J.M. Atopic dermatitis. Special clinical complications. Postgrad Med. 1983; 74(3): 188 - 193, 196 - 199.

58. Cadmus S.D., Sebastian K.R., Warren D. et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split-body control study. Pediatr Dermatol. 2019; 36 (4): 437 - 441.

59. Wolkerstorfer A., Strobos M.A., Glazenburg E.J. et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol. 1998; 39 (2 Pt 1): 226 - 231.

60. Bleehen S.S., Chu A.C., Hamann I. et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995; 133 (4): 592 - 597.

61. Белоусова Т.А., Горячкина М.В. Опыт применения флутиказона пропионата (Кутивейт) в терапии псориаза, экземы и атопического дерматита. Эффективная фармакотерапия. 2010; 9: 24 - 29.

62. Prakash A., Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998; 55(1): 145 - 163.

63. Vernon H.J., Lane A.T., Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol. 1991; 24 (4): 603 - 607.

64. Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol. 1999; 38 (8): 604 - 606.

65. Томилова А.Ю., Торшхоева Р.М., Геворкян А.К., Вознесенская Н.И. Эффективность и безопасность применения мометазонафуроата при атопическом дерматите у детей. Педиатрическая фармакология 2009; 6 (4): 123 - 127.

66. Шаипов Т.С., Мазитова Л.П. Применение мометазонафуроата при лечении атопического дерматита у детей. Педиатрическая фармакология. 2007; 4 (5): 41 - 44.

67. Ненашева Н.М. Особенности атопического дерматита у взрослых пациентов. Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. 2012; (3): 6 - 15.

68. Lane A.T. Efficacy and safety of topical steroids in paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 1997; 8: S24 - S27.

69. Faergemann J., Christensen O., P. et al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2000; 14 (5): 393 - 396.

70. Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J Dermatol Treatm. 1992; 3 (Suppl.2): 13 - 15.

71. Luger T.A. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011; 25 (3): 251 - 258.

72. Bieber T., Vick K., R. et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007; 62 (2): 184 - 189.

73. Кондратьева Ю.С., Кархова В.В. Опыт применения 0,1% метилпреднизолонаацепоната в комплексной терапии стероидчувствительных дерматозов. Вестник дерматологии и венерологии 2016; 1: 93 - 98.

74. Чикин В.В. Метилпреднизолонаацепонат и декспантенол в топической терапии больных атопическим дерматитом. Вестник дерматологии и венерологии 2014; 5: 112 - 116.

75. Lassus A. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children. Int J Dermatol. 1984; 23 (8): 565 - 566.

76. Panja S.K., Gangopadhaya A.K., Sharma S.D. A randomised, double-blind comparison of alclometasone dipropionate 0.05% cream in atopic dermatitis and other dermatoses. Indian J Dermatol. 1988; 33 (1): 1 - 4.

77. Макарова И.В., Гайдук И.М., Жиглинская О.В. и др. Применение 0,05% крема алклометазонадипропионата в терапии атопического дерматита у детей раннего возраста. Вопросы современной педиатрии. 2004; 3 (4): 84 - 87.

78. Короткий Н.Г., Тихомиров А.А., Гамаюнов Б.Н. Оценка клинической эффективности современного стероида алклометазонадипропионата (Афлодерма) в наружной терапии атопического дерматита у детей. Клиническая дерматология и венерология. 2007; 6: 24 - 31.

79. Торопова Н.П., Черкасова Л.А., Платонова И.Н. и др. Опыт применения препарата "Афлодерм" (алклометазонадипропионат) в детской дерматологической практике. Российский журнал кожных и венерических болезней. 2003; 3: 39 - 40.

80. Veien N.K., Hattel T., Justesen O. et al. Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis. J Int Med Res. 1984; 12 (5): 310 - 313.

81. Rajka G., Verjans H.L. Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis. J Int Med Res. 1986; 14 (2): 85 - 90.

82. Abramovits A, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. SKINmed. 2010; 8: 72 - 79.

83. Koopmans B., Lasthein Andersen B., Mork N.J. et al. Multicentre randomized double-blind study of locoidlipocream fatty cream twice daily versus locoidlipocream once daily and locobase once daily. J Dermatol Treat. 1995; 6 (2): 103 - 106.

84. Saki N, Jowkar F, Alyaseen S. et al. Comparison of sertaconazole 2% cream versus hydrocortisone 1% ointment in the treatment of atopic dermatitis. J Dermatolog Treat. 2013; 24 (6): 447 - 449.

85. Reitamo S., Rustin M., Ruzicka T. et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002; 109 (3): 547 - 555.

86. Matheson R., Kempers S., Breneman D. et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008; 7 (3): 266 - 271.

87. Sears H.W., Bailer J.W., Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther. 1997; 19 (4): 710 - 719.

88. Игнатьев Д.В., Кочергин Н.Г. Местные кортикостероиды в практике врача-дерматолога. Особенности гидрокортизона бутирата (локоида). Дерматология. Приложение к журналу ConsiliumMedicum. 2007; 1: 50 - 54.

89. Udompataikul М., Limpa-o-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012; 11 (3): 366 - 374.

90. Udompataikul M., Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. J Eur Acad Dermatol Venereol. 2011; 25 (6): 660 - 665.

91. Сергеев Ю.В., Иванов О.Л., Новиков Д.К. и др. Атопический дерматит: современная диагностика и лечение. Иммунопатология, аллергология, инфектология. 2001; 4: 39 - 63.

92. Ashcroft D.M., Dimmock P., Garside R. et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005; 330 (7490): 516.

93. Ruzicka T., Bieber T., E. et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997; 337 (12): 816 - 821.

94. Reitamo S., Wollenberg A., E. et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000; 136 (8): 999 - 1006.

95. Chen S.L., Yan J., Wang F.S. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010; 21 (3): 144 - 156.

96. Bornhovd E.C., Burgdorf W.H., Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs. 2002; 3 (5): 708 - 712.

97. Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis. Hautarzt. 2003; 54 (5): 432 - 439.

98. Reitamo S., Ortonne J.P., Sand C. et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005; 152 (6): 1282 - 1289.

99. Patel R.R., Vander Straten M.R., Korman N.J. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol. 2003; 139 (9): 1184 - 1186.

100. Wollenberg A., Sidhu M.K., Odeyemi I. et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2008; 159 (6): 1322 - 1330.

101. Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011; 164 (2): 387 - 395.

102. Reitamo S., Mandelin J., Rubins A. et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol. 2009; 48 (4): 348 - 355.

103. Reitamo S., Rustin M., Harper J. et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008; 159 (4): 942 - 951.

104. Mandelin J.M., Remitz A., Virtanen H.M. et al. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. J Dermatolog Treat. 2010; 21 (3): 167 - 170.

105. Mandelin J., Remitz A., Virtanen H.M. et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol. 2010; 90 (2): 170 - 174.

106. Boguniewicz M., Fiedler V.C., Raimer S. et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637 - 644.

107. Елисютина О.Г., Феденко Е.С., Штырбул О.В., Ниязов Д.Д. Применение такролимуса у больных атопическим дерматитом среднетяжелого и тяжелого течения. Первый клинический опыт в России. Российский аллергологический журнал 2011; 6: 68 - 76.

108. Прошутинская Д.В., Бутарева М.М., Иноятова Л.А. Новые возможности терапии атопического дерматита у детей и взрослых. Вестник дерматологии и венерологии 2013; 3: 78 - 82.

109. Самцов А.В., Сухарев А.В., Патрушев А.В., Бондарь О.И. Клиническая эффективность, безопасность и переносимость 0,1% мази такролимус при лечении атопического дерматита средней и тяжелой степени тяжести. Вестник дерматологии и венерологии 2012; 2: 71 - 77.

110. Самцов А.В., Сухарев А.В., Патрушев А.В. Лечение атопического дерматита: преимущества такролимуса перед топическими кортикостероидами. Эффективная фармакотерапия 2014; 19: 4 - 10.

111. Van Leent E.J., Graber M., Thurston M. et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134 (7): 805 - 809.

112. Meurer M., R., Wozel G. et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205 (3): 271 - 277.

113. Wahn U., Bos J., Goodfield M. et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110 (1 Pt 1): 1 - 8.

114. Ho V.C., Gupta A., Kaufmann R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142 (2): 155 - 162.

115. Eichenfield L.F., Lucky A.W., Boguniewicz M. et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002; 46 (4): 495 - 504.

116. Langley R.G., Eichenfield L.F., Lucky A.W. et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children withatopic dermatitis. Pediatr Dermatol. 2008; 25 (3): 301 - 307.

117. Luger T., van Leent E.J., Graeber M. et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001; 144 (4): 788 - 794.

118. Eichenfield L.F., Thaci D., de Prost Y. et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Dermatology 2007; 11: 3 - 17.

119. Reda A.M., Elgendi A., Ebraheem A.I, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019; 30 (4): 366 - 373.

120. Кубанов А.А., Петровский Ф.И. Активированный пиритион цинка (Скин-кап). Механизмы действия. Клиническое применение. Вестник дерматологии и венерологии, 2009; 5: 35 - 42.

121. Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Скин-Кап в терапии атопического дерматита у детей (по результатам Российского многоцентрового исследования КАДЕТ). Российский Аллергологический Журнал 2007; 2: 75 - 81.

122. Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Эффективность и безопасность активированного цинк пиритиона (скин-кап) в лечении атопического дерматита у детей (результаты Российского многоцентрового исследования). Вестник педиатрической фармакологии и нутрициологии 2006; 3 (6): 28 - 31.

123. Нейродерматозы. В кн.: Кожные и венерические болезни: Руководство для врачей. В двух томах. - 2-е изд., перераб. и доп. - Т. 2 / Под ред. Ю.К. Скрипкина и В.Н. Мордовцева, - М.: Медицина, 1999. - С. 9 - 49.

124. Yoshida H., Niimura M., Ueda H. et al. Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine. Ann Allergy. 1989; 62 (6): 507 - 512.

125. Григорьева И., Сергеев А., Манина И., Кудрявцева Е. Иммунопатология и биохимические основы атопических состояний. Врач. 2012; 4: 86 - 91.

126. Морозова С.В., Лусс Л.В. Хлоропирамин: современные аспекты применения. Вопросы современной педиатрии. 2007; 6 (1): 137 - 140.

127. Горячкина М.В., Белоусова Т.А. Хлоропирамин: клинические аспекты применения. Русский медицинский журнал. Аллергология. 2014; 24: 1785 - 1789.

128. Петрова К.С., Петрова Г.А. Хлоропирамин (Супрастин) - современные аспекты применения в терапии аллергодерматозов. Русский медицинский журнал. Фармакотерапия. 2014; 8: 617 - 620.

129. Ревякина В.А. Антигистаминные препараты в клинической практике. Русский медицинский журнал. Аллергология. 2014; 11: 854 - 856.

130. Behrendt H., Ring J. Histamine, antihistamines and atopic eczema. Clin Exp Allergy. 1990; 20 (Suppl 4): 25 - 30.

131. Langeland T., Fagertun H.E., Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy. 1994; 49 (1): 22 - 26.

132. Monroe E.W. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992; 14 (1): 17 - 21.

133. Попова И.С., Матушевская Е.В., Свирщевская Е.В. Двойное слепое плацебо-контролируемое исследование эффективности и переносимости кларотадина при атопическом дерматите. Русс. Мед. Журн. Дерматология, Венерология. 2001; 9 (4): 477 - 483.

134. Hannuksela M., Kalimo K., Lammintausta K. et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993; 70 (2): 127 - 133.

135. La Rosa M., Ranno C., Musarra I. et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy 1994; 73 (2): 117 - 122.

136. Павлова О.В. Опыт применения цетиризина (аллертека) в терапии больных атопическим дерматитом и экземой. Вестник дерматологии и венерологии 2005; (4): 41 - 43.

137. Макарова И.В., Жиглинская О.В., Михайлова Е.А., Сухорукова В.Г. Сравнительная эффективность препаратов цетиризина дженерика (производство Эгис, Венгрия) и оригинального в форме капель в комплексной терапии атопического дерматита у детей раннего возраста. Вопросы современной педиатрии. 2007; 6 (3): 8 - 88.

138. Самсыгина Г.А. Аллергические болезни у детей. - М.: ГЭОТАР-Медиа, 2019. - 272 с.

139. Делягин В.М., Уразбагамбетов А. Применение Супрастинекса (левоцетиризина) при атопии у детей и подростков. Русский медицинский журнал. Педиатрия 2012; (16): 828 - 830.

140. Елисютина О.Г., Феденко Е.С., Федоскова Т.Г., Лусс Л.В. Эффективность терапии левоцетиризином больных с аллергодерматозами. Росс. Аллергол. Журнал, 2012, 5: 69 - 75.

141. Тамразова О.Б. Патогенетическая терапия детей, страдающих тяжелыми формами атопического дерматита. Русский медицинский журнал. Педиатрия. 2013; (2): 108 - 114.

142. Нажмутдинова Д.К., Швец О.И. Левоцетиризин: перезагрузка. Русский медицинский журнал. Дерматология. 2011; 21: 1324 - 1326.

143. Камаев А.В., Трусова О.В., Камаева И.А. Зуд при атопическом дерматите у детей: известные механизмы и возможности его долгосрочного контроля. Русский медицинский журнал. 2015; 3: 142 - 146.

144. Монахов С.А., Коржачкина Н.Б., Олисова О.Ю. Узковолновая фототерапия 311 нм в лечении больных атопическим дерматитом. Российский журнал кожных и венерических болезней. 2012; 3: 25 - 27.

145. Majoie I.M., Oldhoff J.M., van Weelden H. et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60: 77 - 84.

146. Reynolds N.J., Franklin V., Gray J.C. et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001; 357 (9273): 2012 - 2016.

147. Clayton T.H., Clark S.M., Turner D., Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007; 32 (1): 28 - 33.

148. Seccombe L., Wynne M.D., Clancy C. et al. A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit. Photodermatol Photoimmunol Photomed. 2021; 37 (1): 34 - 38.

149. Gambichler T., Othlinghaus N., Tomi N.S. et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160 (3): 652 - 658.

150. Bogaczewicz J., Malinowska K., Sysa-Jedrzejowska A., Wozniacka A. Medium-dose ultraviolet A1 phototherapy improves SCORAD index and increases mRNA expression of interleukin-4 without direct effect on human defensin-1, interleukin-10, and interleukin-31. Int J Dermatol. 2016; 55 (7): e380 - e385.

151. Tzaneva S., Seeber A., Schwaiger M. et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001; 45: 503 - 507.

152. Malinowska K., Wozniacka A., Bogaczewicz J. The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis. Postepy Dermatol Alergol. 2020; 37 (6): 962 - 967.

153. Abeck D., Schmidt T., Fesq H. et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol. 2000; 42 (2 Pt 1): 254 - 257.

154. Pugashetti R., Lim H.W., Koo J. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? J Dermatolog Treat. 2010; 21 (6): 326 - 330.

155. Tzaneva S., Kittler H., Holzer G. et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol. 2010; 162 (3): 655 - 660.

156. Garritsen F.M., Brouwer M.W., Limpens J., Spuls P.I. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014; 170 (3): 501 - 513.

157. A., Aranegui B., J.A. et al. Phototherapy in atopic dermatitis: a systematic review of the literature. Actas Dermosifiliogr. 2015; 106 (5): 387 - 401.

158. Uetsu N., Horio T. Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy. J Dermatol. 2003; 30 (6): 450 - 457.

159. Физическая и реабилитационная медицина. Национальное руководство. / Под ред. Г.Н. Пономаренко., М.: ГЭОТАР-Медиа, 2016 г. 688 с.

160. Частная физиотерапия: Учебное пособие / Под ред. Г.Н. Пономаренко. - М.: ОАО "Издательство "Медицина", 2005, 744 с.

161. Patrizi A., Raone B., Ravaioli G.M. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015; 8: 511 - 520.

162. Dogra S., Mahajan R.; Indian Association of Dermatologists, Venereologists and Leprologists. Phototherapy for atopic dermatitis. Indian J Dermatol VenereolLeprol. 2015; 81 (1): 10 - 15.

163. Кубанова А.А., Самсонов В.А., Волнухин В.А. и др. Терапия больных псориазом, атопическим дерматитом и витилиго узкополосным средневолновым ультрафиолетовым излучением с длиной волны 311 нм. Медицинская технология N ФС-2006/250 от 15 августа 2006 года. Вестник дерматологии и венерологии 2008: 3: 17 - 20.

164. Thompson K.G., Kim N. Distinguishing myth from fact: photocarcinogenesis and phototherapy. DermatolClin. 2020; 38 (1): 25 - 35.

165. Paller A.S., Siegfried E.C., Thagi D. et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020; 83 (5): 1282 - 1293.

166. Paller A.S., Bansal A., Simpson E.L. et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020; 21 (1): 119 - 131.

167. Simpson E.L., Paller A.S., Siegfried E.C. et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial. JAMA Dermatol. 2020; 156 (1): 44 - 56.

168. Cork M.J., D., Eichenfield L.F. et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020; 182 (1): 85 - 96.

169. Simpson E.L., Bieber T., Guttman-Yassky E. et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016; 375 (24): 2335 - 2348.

170. Blauvelt A., de Bruin-Weller M., Gooderham M. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10086): 2287 - 2303.

171. de Bruin-Weller M., D., Smith C.H. et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD ). Br J Dermatol. 2018; 178(5): 1083 - 1101.

172. D., L Simpson E., Deleuran M. et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019; 94 (2): 266 - 275.

173. Cork M.J., Eckert L., Simpson E.L. et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2019 Jun 9: 1 - 9.

174. Snast I., Reiter O., Hodak E. et al. Are biologies efficacious in atopic dermatitis? asystematic review and meta-analysis. Am J Clin Dermatol. 2018; 19 (2): 145 - 165.

175. Wang F.P, Tang X.J., Wei C.Q. et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2018; 90 (2): 190 - 198.

176. Czech W., Brautigam M., Weidinger G., E. Body weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653 - 659.

177. Harper J.I., Ahmed I., Barclay G. et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52 - 58.

178. Granlund H., Erkko P., Remitz A. et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol 2001; 81: 22 - 27.

179. Zurbriggen B., Wuthrich B., Cachelin A.B. et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999; 198: 56 - 60.

180. Hijnen D.J., ten Berge O., Timmer-de Mik L.et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 2007; 21: 85 - 89.

181. Schmitt J., Schmitt N., Meurer M. Cyclosporin in the treatment of patients with atopic eczema a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21 (5): 606 - 619.

182. Amor K.T., Ryan K., Menter A. The use of cyclosporine in dermatology: Part I. J Am Acad Dermatol 2010; 63 (6): 925 - 946.

183. Wollenberg A., Barbarot S., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32 (6): 850 - 878.

184. Шамов Б.А. Атопический дерматит: клинические проявления и лечение. Дневник Казанской медицинской школы. 2014; 1 (4): 63 - 65.

185. Jung M.Y., Chung J.Y., Lee H.Y. et al. Antibiotic susceptibility of Staphylococcus aureus in atopic dermatitis: current prevalence of methicillin-resistant Staphylococcus aureus in Korea and treatment strategies. Ann Dermatol. 2015; 27 (4): 398 - 403.

186. Lubbe J. Secondary infections in patients with atopic dermatitis. Am J ClinDermatol 2003; 4 (9): 641 - 654.

187. Масюкова С.А., Гладько Е.В., Тарасенко Г.Н. и др. Фузидиевая кислота в лечении пиодермитов и аллергодерматозов, осложненных бактериальной инфекцией. Вестник дерматологии и венерологии. 2007; 6: 54 - 57.

188. Дворянкова Е.В., Корсунская И.М., Захарова А.Б., Жуковский Р.О. Атопический дерматит, осложненный вторичной инфекцией: подходы к терапии. Эффективная фармакотерапия. 2011; 26: 74 - 76.

189. Ларькова И.А. Эффективная терапия атопического дерматита у детей, осложненного вторичной инфекцией. Медицинский совет. 2016; 1: 162 - 167.

190. Матушевская Е.В., Свирщевская Е.В. Атопический дерматит в практике врача-дерматовенеролога: рациональный выбор терапии. Русский медицинский журнал. 2013; 21 (8): 410 - 412.

191. Gong J.Q., Lin L., Lin T. et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006; 155: 680 - 687.

192. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119: 189 - 198.

193. Альбанова В. Наружное лечение атопического дерматита. Врач. 2006; 2: 76 - 78.

194. Батыршина С.В., Хаертдинова Л.А. Концепция местной терапии больных атопическим дерматитом. Практическая медицина. 2009; 35 (3): 41 - 45.

195. Wachs G.N., Maibach H.I. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323 - 328.

196. Schuttelaar M.L., Coenraads P.J. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. J Eur Acad Dermatol Venereol 2008; 22: 1076 - 1082.

197. Васенова В.Ю., Бутов Ю.С. Применение Полькортолона ТС для лечения зудящих дерматозов, осложненных вторичной инфекцией. Русский медицинский журнал 2013; 21 (22): 1096 - 1098.

198. Скрипкин Ю.К., Хамаганова И.В. Опыт применения аэрозолей оксикорт и полькортолон ТС в лечении аллергических дерматозов, осложненных пиодермией. Вестник дерматологии и венерологии. 2004; 1: 42 - 43.

199. Ramsay C., Savoie J., Gilbert M. et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 1): S 15 - 22.

200. Hjorth N., Schmidt H., Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126 - 131.

201. Тарасова М.В., Марина Т.В., Сорокина Е.А. и др. Целесообразность применения комбинированных топических глюкокортикостероидов в комплексной терапии атопического дерматита. Журнал научных статей Здоровье и образование в XXI веке. 2008; 10 (3): 383.

202. Кубанова А.А. Прошутинская Д.В., Текучева Л.В., Авдиенко И.Н. Интегральный подход к наружной терапии больных атопическим дерматитом. Вестник дерматологии и венерологии. 2010; 1: 20 - 26.

203. Ненашева Н.М. Особенности местной (наружной) терапии осложненного инфекцией атопического дерматита. РМЖ. 2015; 23 (19): 1159 - 1165.

204. Кунгуров Н.В., Кениксфест Ю.В., Кохан М.М. и др. Комбинированная наружная терапия осложненных дерматозов. Клиническая дерматология и венерология. 2005; 2: 33 - 37.

205. Niebuhr M., Mai U., Kapp A., Werfel T. Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. ExpDermatol. 2008; 17 (11): 953 - 957.

206. Boguniewicz M., Sampson H., Leung S. et al. Effects of cefuroxime axetil on Staphylococcus aureus colonizing and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001; 108: 651 - 652.

207. Тренева М.С., Пампура А.Н. Стратегия выбора антибактериальных препаратов у детей с микробным инфицированием атопического дерматита. Практическая медицина. 2011; 3 (51): 136 - 139.

208. Boguniewicz M., Leung D.Y. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010; 125 (1): 4 - 13.

209. Tognetti L., Martinelli C., Berti S. et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol. 2012; 26 (8): 931 - 941.

210. Petry V., Bessa G.R., Poziomczyck C.S. et al. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012; 87 (5): 729 - 734.

211. Wollenberg A. Eczema herpeticum. Chem Immunol Allergy. 2012; 96: 89 - 95.

212. Niimura M., Nishikawa T. Treatment of eczema herpeticum with oral acyclovir. Am J Med. 1988; 85 (2A): 49 - 52.

213. Bussmann C., Bockenhoff A., Henke H. et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006; 118: 1292 - 1298.

214. Darsow U., Forer I., Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep 2011; 11: 277 - 283.

215. Bae J.M., Choi Y.Y., Park C.O. et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 132: 110 - 117.

216. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982; 107: 597 - 602.

217. Glover M.T., Atherton D.J. A double-blind controlled trial of hyposensitization to Dermatophagoidespteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22: 440 - 446.

218. Zachariae H., Cramers M., Herlin T. et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 114: 48 - 54.

219. Елисютина О.Г., Феденко Е.С. Место специфической иммунотерапии в лечении больных атопическим дерматитом, осложненным рецидивирующей пиодермией. Физиология и патология иммунной системы. Физиология и патология иммунной системы. 2006; (8): С. 15.

220. Novak N., Bieber T., Hoffmann M. et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012; 130: 925 - 931 e4.

221. Pajno G.B., Caminiti L., Vita D. et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120: 164 - 170.

222. Qin Y.E., Mao J.R., Sang Y.C., Li W.X. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoidesfarinae drops in patients with atopic dermatitis. Int J Dermatol 2014; 53: 650 - 655.

223. Liu L., Guo D., Liang Q. et al. The efficacy of sublingual immunotherapy with Dermatophagoidesfarinae vaccine in a murine atopic dermatitis model. Clin Exp Allergy 2015; 45: 815 - 822.

224. Roduit C., Frei R., Loss G. et al. Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol 2012; 130: 130 - 136 e5.

225. Perkin M.R., Logan K., Tseng A. et al. Randomized trial of introduction of allergenic foods in breast-fed infants. N Engl J Med 2016; 374: 1733 - 1743.

226. Prell C., Koletzko B. Breastfeeding and Complementary Feeding. DtschArztebl Int. 2016; 113(25): 435 - 444.

227. Vandenplas Y., Al-Hussaini B., Al-Mannaei K. et al. Prevention of Allergic Sensitization and Treatment of Cow"s Milk Protein Allergy in Early Life: The Middle-East Step-Down Consensus. Nutrients. 2019 Jun 26; 11(7).

228. Gruber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. Exp Rev Clin Immunol 2012; 8: 17 - 19.

229. Cuello-Garcia C.A., Brozek J.L., Fiocchi A. et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2015; 136: 952 - 961.

230. Panduru M., Panduru N.M., C.M., Tiplica G.S. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015; 29 (2): 232 - 242.

231. Muraro A., Halken S., Arshad S.H. et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy 2014; 69: 590 - 601.

232. Kantor R., Kim A., Thyssen J.P., Silverberg J.I. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol 2016; 75: 1119 - 1125 el.

233. Kathuria P., Silverberg J.I. Association of pollution and climate with atopic eczema in US children. Pediatr Allergy Immunol 2016; 27: 478 - 485.

234. Morgenstern V., Zutavern A., Cyrys J. et al. Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children. Am J Respir Crit Care Med 2008; 177: 1331 - 1337.

235. Hidaka T., Ogawa E., Kobayashi E.H. et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol 2017; 18: 64 - 73.

236. Ricci G., Bendandi B., Aiazzi R. et al. Three years of Italian experience of an educational program for parents of young children affected by atopic dermatitis: improving knowledge produces lower anxiety levels in parents of children with atopic dermatitis. Pediatr Dermatol. 2009; 26: 1 - 5.

237. Staab D., Diepgen T.L., Fartasch M. et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006; 332: 933 - 938.

238. Lambert J., Bostoen J., Geusens B. et al. A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results. Arch Dermatol Res. 2011; 303: 57 - 63.

239. Kupfer J., Gieler U., Diepgen T.L. et al. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial. J PsychosomRes. 2010; 68 (4): 353 - 358.

240. Staab D., von Rueden U., Kehrt R. et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol. 2002; 13: 84 - 90.

241. Kiriyama T., Sugiura H., Uehara M. Residual washing detergent in cotton clothes: a factor of winter deterioration of dry skin in atopic dermatitis. J Dermatol. 2003; 30: 708 - 712.

242. Schmid-Wendtner M.H., Korting H.C. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006; 19: 296 - 302.

243. Simpson E., Trookman N.S., Rizer R.L. et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol. 2012; 29: 590 - 597.

244. Hon K.L., Leung T.F., Wong Y. et al. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol. 2005; 30: 351 - 354.

245. Wollenberg A., Vogel S., Renner E.D. [Vaccinations with atopic dermatitis and other chronic inflammatory skin diseases]. Hautarzt 2010; 61: 985 - 993.

246. Bath-Hextall F., Delamere F., Williams H. Dietary exclusions for improving established atopic eczema in adults and children systematic review. Allergy 2009; 64: 258 - 264.

247. Электронный ресурс https://base.garant.ru/70647158/53f89421bbdaf741eb2d1ecc4ddb4c33/

248. [Аллергология и иммунология: национальное руководство / Под ред. Хаитова Р.М., Ильиной Н.И. - М.: ГЭОТАР-Медиа, 2009.

249. Campana R., Dzoro S., Mittermann I. et al. Molecular aspects of allergens in atopic dermatitis. CurrOpin Allergy Clin Immunol. 2017; 17(4): 269 - 277.

250. Cartledge N, Chan S. Atopic Dermatitis and Food Allergy: A Paediatric Approach. CurrPediatr Rev. 2018; 14(3): 171 - 179. doi: 10.2174/1573396314666180613083616. PMID: 29895253.

251. Darsow U., Laifaoui J., Kerschenlohr K. et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: A European multicenter study. Allergy. 2004; 59: 1318 - 1325.

252. Tamagawa-Mineoka R., Katoh N. Atopic Dermatitis: Identification and Management of Complicating Factors. Int J Mol Sci. 2020; 21 (8): 2671.

253. Werfel T., Heratizadeh A., Niebuhr M. et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015; 136(1): 96 - 103. e9.

254. Caut C., Leach M., Steel A. Dietary guideline adherence during preconception and pregnancy: A systematic review. Matern Child Nutr. 2020; 16(2): e12916.

255. Sugita K., Akdis C.A. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int. 2020; 69 (2): 204 - 214.

256. Fedenko E., Elisyutina O., Shtyrbul O. et al. Microarray-based IgE serology improves management of severe atopic dermatitis in two children. Pediatr Allergy Immunol. 2016; 27(6): 645 - 649.

257. Alexander D.D., Cabana M.D. Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. J Pediatr Gastroenterol Nutr. 2010; 50 (4): 422 - 430.

258. Niggemann B., Reibel S., Wahn U. The atopy patch test (APT)-a useful tool for the diagnosis of food allergy in children with atopic dermatitis // Allergy. - 2000. - T. 55. - N. 3. - C. 281 - 285.

259. Sampson H.A., Albergo R. Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis // Journal of Allergy and Clinical Immunology. - 1984. - T. 74. - N. 1. - C. 26 - 33.

260. Roehr C.C. et al. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis // Journal of allergy and clinical immunology. - 2001. - T. 107. - N. 3. - C. 548 - 553.